Search Results
Jun 04, 2025, 02:56 ET Vollständige Daten zur Dosiseskalation zeigen anhaltend hohe Ansprechraten und ein günstiges Sicherheitsprofil von ISB 2001, einem ersten trispezifischen Antikörper gegen BCMA × CD38 × CD3, zur Behandlung von rezidiviertem/refraktärem multiplem Myelom
Die ORR betrug 79 % (26/33), einschließlich einer CR/sCR-Rate von 30 % (10/33), mit einer medianen Nachbeobachtungszeit von 6,3 Monaten (Bereich: 1–16).Von den 10 Patienten, die eine CR/sCR erreichten, konnten acht auf minimale Restkrankheit (MRD)
More news about: Ichnos Glenmark Innovation
Jun 03, 2025, 12:28 ET Les données complètes de l'escalade de dose montrent des taux de réponse invariablement élevés et un profil de sécurité favorable pour l'ISB 2001, un anticorps trispécifique BCMA × CD38 × CD3, premier de sa classe, pour le traitement du myélome multiple récidivant/réfractaire
anti-CD38, l'ORR était de 72 %, avec un taux de CR/sCR de 24 %.Chez 19 patients n'ayant pas reçu de traitement ciblant les lymphocytes T (TCDT), y compris des anticorps bispécifiques et/ou une thérapie CAR-T, l'ORR était de 84 %, avec un taux de CR/sCR de 32 %.Parmi les 14 patients
More news about: Ichnos Glenmark Innovation
Jun 03, 2025, 10:45 ET DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
lenalidomide for maintenance has not been established. The primary endpoint is PFS, and secondary endpoints include overall CR or better rate, and overall MRD-negativity (in patients with CR or better). The median age is 61.0 (range, 32-70) years for patients in the D-VRd arm and 59.0 (range, 31-70) years for
More news about: Johnson & Johnson
Jun 03, 2025, 07:19 ET Fibe Unveils Digital FDs, Strengthening Its Role as a One-Stop Financial Partner
been certified with ISO/IEC 27001 for its Information Security Management System (ISMS). Fibe has disbursed more than 8 million+ loans worth Rs. 33,000 Cr+ since inception through its lending partners. The company has tied up with more than 8,000 partners to expand its impact and
More news about: Fibe
Jun 02, 2025, 21:25 ET 亞盛醫藥Bcl-2抑制劑Lisaftoclax針對維奈克拉治療失敗患者口頭報告數據強勁，全球競爭優勢明顯|直擊2025 ASCO
MPAL患者中，ORR為 83.3%, 其中33.3%的患者獲 CR/CRi ，50%的患者獲PR。在 44 例療效可評估R/R AML/MPAL 患者中，ORR為 43.2%，其中31.8% 的患者獲CR/CRi ，4.5%的患者獲PR，6.8% 的患者獲MLFS。- 在15例療效可評估的 ND MDS/慢性粒單核細胞白血病（CMML）患者中，ORR為 80%，其中40%的患者獲CR，40%的患者獲骨髓CR（mCR）。22 例療效可評估的 R/R MDS/CMML 患者中，ORR為 50%，其中27.3%的患者獲 CR，18.2%的患者獲 mCR，4.5%的患者獲PR。
More news about: 亞盛醫藥
Jun 02, 2025, 13:46 ET Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
doses ≥ 50 µg/kg: The ORR was 79% (26/33), including a CR/sCR rate of 30% (10/33), with a median follow- up of 6.3 months (range: 1–16).Of the 10 patients achieving CR/sCR, eight were evaluable for minimal residual disease (MRD), and six achieved MRD
More news about: Ichnos Glenmark Innovation
Jun 02, 2025, 13:37 ET Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
doses ≥ 50 µg/kg: The ORR was 79% (26/33), including a CR/sCR rate of 30% (10/33), with a median follow- up of 6.3 months (range: 1–16).Of the 10 patients achieving CR/sCR, eight were evaluable for minimal residual disease (MRD), and six achieved MRD
More news about: Ichnos Glenmark Innovation
Jun 02, 2025, 09:25 ET URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
regarding UroGen's NDA for UGN-102, which stated that "[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret," and that the FDA had "recommended a randomized trial design to the Applicant several times
More news about: Robbins Geller Rudman & Dowd LLP
Jun 02, 2025, 08:03 ET TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
weekly administration of IFx-Hu2.0 for up to 3 doses followed by rechallenge with anti-PD(L)-1 therapy, demonstrated an overall response rate of 63% (2CR, 5 PR) with duration of responses ranging from 6 to 33 months with 5 ongoing responses as of last follow-up in June 2024.
More news about: TuHURA Biosciences, Inc.
May 30, 2025, 18:50 ET Waaree Solar Americas Signs 586 MW Module Supply Agreement with Leading U.S. IPP, Secures $176 Million (INR 1500 Cr) Order
multimedia:https://www.prnewswire.com/news-releases/waaree-solar-americas-signs-586-mw-module-supply-agreement-with-leading-us-ipp-secures-176-million-inr-1500-cr-order-302469894.html
More news about: Waaree Solar Americas Inc.
May 30, 2025, 10:25 ET URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
the briefing document, the FDA stated: "[g]iven that [the ENVISION trial] lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret." The FDA also said it had "recommended a randomized trial design to the Applicant several
More news about: Faruqi & Faruqi, LLP
May 29, 2025, 20:40 ET URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit
effective. In the briefing document, the FDA stated: "[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret." The FDA also said it had "recommended a randomized trial design to the Applicant several
More news about: Robbins LLP
May 29, 2025, 17:30 ET URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
regarding UroGen's NDA for UGN-102, which stated that "[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret," and that the FDA had "recommended a randomized trial design to the Applicant several times
More news about: Robbins Geller Rudman & Dowd LLP
May 29, 2025, 11:19 ET UBS celebrates the craft of couture with Dior and Carine Roitfeld through new experiential exhibition
ABOUT CARINE ROITFELD Carine is a leading fashion industry figure, the Founder and Editor-in-Chief of CR Fashion Book, headquartered in NYC, she was also previously the Editor-in-Chief of Vogue Paris for almost a decade. Known for her bold and provocative
More news about: UBS House of Craft x Dior
May 29, 2025, 09:00 ET CPSC Warns Consumers to Immediately Stop Using Petgravity Cat Toys Due to Risk of Serious Injury or Death to Children from Ingestion Hazard; Violations of Federal Regulations for Consumer Products with Coin Batteries; Sold on Amazon by Sanchio Store
on the top of the packaging. The products include an automatic car toy, remote control, feather accessory, tail rod, charging cable and a preinstalled CR2032 lithium battery in the remote control. These products may have also been sold by other sellers. These products were manufactured in
More news about: U.S. Consumer Product Safety Commission
May 29, 2025, 04:47 ET Fermenta FY25 Revenues INR 481.3 cr, up 39% YoY; Net Profit INR 76.4 cr vs year-ago loss
content:https://www.prnewswire.com/in/news-releases/fermenta-fy25-revenues-inr-481-3-cr-up-39-yoy-net-profit-inr-76-4-cr-vs-year-ago-loss-302468098.html
More news about: Fermenta Biotech Limited
May 29, 2025, 04:14 ET Suraj Estate Developers Reports Robust FY25 Performance with 33% Growth in Revenue and 48% Jump in PAT
Y-o-Y Total Income (Rs cr) 553.2
More news about: Suraj Estate Developers
May 28, 2025, 06:45 ET Canada Nickel Reports Continued Exploration Success at Reid, Mann West and Deloro
Pt g/t Cr % Fe %
More news about: Canada Nickel Company Inc.
May 27, 2025, 09:03 ET CR Fitness Holdings Opens 85th Crunch Fitness Location with State-of-the-Art Facility in Gainesville, GA
Tony Scrimale, CEO of CR Fitness Holdings. "This 3.0 location takes everything our members love about Crunch to the next level, with premium amenities, the latest equipment, and a fun, welcoming atmosphere that caters to everyone." CR Fitness Holdings is on track to operate 100
More news about: CR Fitness Holdings, LLC.
May 27, 2025, 09:00 ET AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
benefit.4,5 The results show that among 33 untreated patients, the primary endpoint of composite complete response (CCR) rate, defined as CR + clinical CR (CR with minimal skin abnormality), was 70% (95% CI, 51.3-84.4) with a median duration of CCR of 9.8 months. ORR was 85%.4 In the 51
More news about: AbbVie
May 26, 2025, 03:22 ET Cosmic CRF Limited Reports H2 & FY25 Performance Highlights
bankAcquired land parcel to set up state of art factory to produce forged components for wagons with installed capacity of 7200 MTPA, Capex would be ~45Cr and would be funded through internal accruals and / or term loan from bank. Production expected to start by February 2026Received
More news about: Cosmic CRF Limited
May 23, 2025, 11:10 ET PeproMene Bio, Inc. und das Institute for Follicular Lymphoma Innovation (IFLI) geben bekannt, dass der erste Patient mit follikulärem Lymphom (FL), der mit BAFF-R zielgerichteten CAR-T-Zellen (PMB-CT01) behandelt wurde, ein vollständiges Ansprechen erreicht hat
der bei City of Hope mit PMB-CT01 behandelt wurde, erreichte eine CR einen Monat nach der Behandlung.Insgesamt 7/7 r/r B-NHL-Patienten, einschließlich MCL, DLBCL und FL, die mit PMB-CT01 behandelt wurden, haben eine anhaltende CR (1 bis mehr als 29 Monate) erreicht, wobei ausschließlich Grad 1
More news about: PeproMene Bio, Inc.
May 22, 2025, 17:20 ET Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
adjusted rates of response for olutasidenib vs. ivosidenib were comparable (adjusted point estimate favored olutasidenib for CR and ivosidenib for CR+CRh), while a longer duration of CR+CRh was observed with olutasidenib. Adjusted OS was similar between the two groups, although the hazard ratio (HR) favored
More news about: Rigel Pharmaceuticals, Inc.
May 22, 2025, 17:02 ET Taiho Oncology Presents Data at the 2025 American Society of Clinical Oncology Annual Meeting
first-line induction chemotherapy. Complete remission (CR) and CR with incomplete hematologic recovery rates were 46.5% and 63.4%, respectively. Median time to CR was 2.4 months. Median CR duration was not reached; among patients who achieved CR, 80% maintained that status at 6 months and 75.3% at 12
More news about: Taiho Oncology
May 22, 2025, 17:00 ET Novita Highlights Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at 2025 ASCO Annual Meeting
metastases.Notable outcomes include continued CR in a cervical cancer patient, target lesion CR in an endometrial cancer patient, pathological CRs in a pancreatic cancer patient and a patient with gastroesophageal junction adenocarcinoma, clinical CR in a cutaneous squamous cell carcinoma patient,
More news about: Novita Pharmaceuticals, Inc.